Managed Access Programs for ABL001, Asciminib
- Conditions
- Chronic Myeloid Leukemia in Chronic Phase
- First Posted Date
- 2020-04-24
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT04360005
Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease
- Conditions
- Covid-19
- Interventions
- Drug: PlaceboDrug: HCQDrug: HCQ+AZT
- First Posted Date
- 2020-04-22
- Last Posted Date
- 2021-10-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 20
- Registration Number
- NCT04358081
- Locations
- 🇺🇸
Novartis Investigative Site, Seattle, Washington, United States
An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- First Posted Date
- 2020-04-20
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 564
- Registration Number
- NCT04353492
- Locations
- 🇺🇸
Fullerton Neuro and Headache Ctr, Fullerton, California, United States
🇺🇸CU Anschutz Med Campus, Aurora, Colorado, United States
🇺🇸Christiana Care Health Services, Newark, Delaware, United States
A Study to Assess Efficacy and Safety of Eltrombopag in Combination With a Short Course of Dexamethasone in Patients With Newly Diagnosed ITP
- Conditions
- Immune Thrombocytopenia (ITP)
- Interventions
- First Posted Date
- 2020-04-15
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 28
- Registration Number
- NCT04346654
- Locations
- 🇩🇪
Novartis Investigative Site, Kronach, Germany
Ruxolitinib Managed Access Program (MAP) for Patients Diagnosed With Severe/Very Severe COVID-19 Illness
- Conditions
- Severe/Very Severe COVID-19 Illness
- First Posted Date
- 2020-04-07
- Last Posted Date
- 2021-01-26
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT04337359
Lamprene Multiple Patient Program
- Conditions
- Non-Tuberculous Mycobacterial (NTM) Infections
- First Posted Date
- 2020-04-03
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT04334070
Combination of Eltrombopag With Immunosuppressive Therapy in East-Asian Patients With Severe Aplastic Anemia
- Conditions
- Severe Aplastic Anemia (SAA)
- Interventions
- First Posted Date
- 2020-03-31
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 36
- Registration Number
- NCT04328727
- Locations
- 🇨🇳
Novartis Investigative Site, Kaohsiung, Taiwan
Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2020-03-26
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 31
- Registration Number
- NCT04323436
- Locations
- 🇪🇸
Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain
🇺🇸Massachusetts General Hospital Liver and Kidney TX, Boston, Massachusetts, United States
Study to Assess Safety, Tolerability and Phamacokinetics of KAE609 Administered Intravenously in Healthy Subjects
- Conditions
- Malaria
- Interventions
- Drug: KAE609Drug: Placebo
- First Posted Date
- 2020-03-25
- Last Posted Date
- 2021-12-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 57
- Registration Number
- NCT04321252
- Locations
- 🇧🇪
Novartis Investigative Site, Antwerpen, Belgium
BCMA-directed CAR-T Cell Therapy in Adult Patients With Multiple Myeloma
- First Posted Date
- 2020-03-23
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 96
- Registration Number
- NCT04318327
- Locations
- 🇺🇸
University of Chicago Medical Center Hematology and Oncology, Chicago, Illinois, United States
🇺🇸Beth Israel Deaconess Medical Cente KS121, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute Main Centre, Boston, Massachusetts, United States